2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Potassium Channel

Potassium Channel

KcsA

Potassium Channel

Related Products

PDF 4.25 MB

Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. They form potassium-selective pores that span cell membranes. Potassium channels are found in most cell types and control a wide variety of cell functions. Potassium channels function to conduct potassium ions down their electrochemical gradient, doing so both rapidly and selectively. Biologically, these channels act to set or reset the resting potential in many cells. In excitable cells, such asneurons, the delayed counterflow of potassium ions shapes the action potential. By contributing to the regulation of the action potential duration in cardiac muscle, malfunction of potassium channels may cause life-threatening arrhythmias. Potassium channels may also be involved in maintaining vascular tone.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B1140S
    Diazoxide-d3
    		Activator
    Diazoxide-d3 is deuterium labeled Diazoxide. Diazoxide (Sch-6783) is an ATP-sensitive potassium channel activator, has the potential for hyperinsulinism treatment.
    Diazoxide-d<sub>3</sub>
  • HY-P1886
    Kv3, Channel Containing Protein (567-585)
    Kv3, Channel Containing Protein (567-585) corresponds to amino acids 567 to 585 fragment of the Kv3.1b channel containing protein. Kv3 channel protein is expressed by parvalbumin (PV)-containing pallidal neurons .
    Kv3, Channel Containing Protein (567-585)
  • HY-B0259R
    Indapamide (Standard)
    		Inhibitor
    Indapamide (Standard) is the analytical standard of Indapamide. This product is intended for research and analytical applications. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy.
    Indapamide (Standard)
  • HY-P5182
    HsTX1
    		Inhibitor
    HsTX1, from the scorpion Heterometrus spinnifer, is a 34-residue, C-terminally amidated peptide cross-linked by four disulfide bridges. HsTX1, an the inhibitor of potassium channel, with IC50 for Kv1.3 of 12 pM inhibits TEM cell activation and attenuates inflammation in autoimmunity.
    HsTX1
  • HY-124396
    Lanceotoxin A
    Lanceotoxin A is a potent potassium channel inhibitor with activity in regulating cell membrane potential. Lanceotoxin A showed a significant negative correlation with extracellular metabolites in patients after metabolic surgery. The presence of lanceotoxin A may affect the composition of intestinal microorganisms and its association with insulin resistance. Lanceotoxin A may play an important role in the improvement of metabolic syndrome and diabetes.
    Lanceotoxin A
  • HY-173618
    LQFM020
    		Activator
    LQFM020 is an orally active pyrazole derivative. LQFM020 inhibits Ca+ and activates K+ and NO/cGMP channels to inhibit vasoconstriction. LQFM020 has anti-inflammatory and anti-analgesic activities.
    LQFM020
  • HY-153952
    Immuno modulator-1
    		Inhibitor
    Immuno modulator-1 (compound 22) inhibits TNFα and IL-2 secretion in human peripheral blood mononuclear cells (hPBMC), with IC50 values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μM.
    Immuno modulator-1
  • HY-120226A
    VU714 oxalate
    VU714 oxalate is a Kir7.1 channel inhibitor that enhances block by structurally unrelated inhibitors and influences the pharmacology of Kir channels through its interactions with key residues.
    VU714 oxalate
  • HY-117528
    WAY-123398
    		Inhibitor
    WAY-123398 is a class III antiarrhythmic agent. WAY-123398 is a selective blocker of the delayed rectifier K+ current.
    WAY-123398
  • HY-119211
    LY 97241
    		Inhibitor
    LY 97241 accelerates the apparent rate of inactivation of transient outward K current. LY 97241 is an antiarrhythmic drug.
    LY 97241
  • HY-N2433
    Paederosidic acid methyl ester
    		Activator 99.81%
    Paederosidic acid methyl ester is a ATP‐sensitive K+ channel activator, isolated from P. scandens. Paederosidic acid methyl ester exhibits significant central analgesic activity, and enhances the threshold of pain by activating ATP‐sensitive K+ channel in the brain and spinal cord level.
    Paederosidic acid methyl ester
  • HY-W050000R
    OR-1855 (Standard)
    		Activator
    Tanshinone IIA sulfonate (sodium) (Standard) is the analytical standard of Tanshinone IIA sulfonate (sodium). This product is intended for research and analytical applications. Tanshinone IIA sulfonate (sodium) is a derivative of tanshinone IIA, which acts as an inhibitor of store-operated Ca2+ entry (SOCE), and is used to treat cardiovascular disorders.
    OR-1855 (Standard)
  • HY-N1934R
    Dihydroberberine (Standard)
    		Inhibitor
    Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy.
    Dihydroberberine (Standard)
  • HY-118628A
    BML264
    		Agonist
    BML264 ((E)-N-(p-amylcinnamoyl) anthranilic acid) is an agonist for TREK-1. BML264 can be used to study diseases associated with TASK1 dysfunction.
    BML264
  • HY-122560
    VU0134992
    		Inhibitor
    VU0134992 is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV.
    VU0134992
  • HY-P5156
    BDS-I
    		Inhibitor
    BDS-I known as blood depressing substance, is a marine toxin which can be extracted from Anemonia sulcata. BDS-I is a specific inhibitor of Potassium Channel, targeting to Kv3.4. BDS-I inhibits Aβ1-42-induced enhancement of KV3.4 activity, caspase-3 activation, and abnormal nuclear morphology of NGF-differentiated PC-12 cells. BDS-I reverts the Aβ peptide-induced cell death.
    BDS-I
  • HY-117403
    AB-FUBICA
    		Activator
    AB-FUBICA (Compound 13) is a CB1 and CB2 receptor agonist that activates G-protein coupled inwardly rectifying potassium channels (GIRK) by binding to CB1 and CB2 receptors, displaying notable cannabinoid-like activity. AB-FUBICA has EC50 values of 21 nM for CB1 and 15 nM for CB2. AB-FUBICA may be suitable for studying pain management, neurodegenerative diseases, and inflammation-related mechanisms.
    AB-FUBICA
  • HY-B1194A
    Tetramisole
    		Agonist
    Tetramisole is an orally active, selective inward rectifier potassium channel agonist with an EC50 of approximately 30 μM for the Kir2.1 subunit. Tetramisole is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure.
    Tetramisole
  • HY-14924
    Inakalant
    		Inhibitor
    Inakalant is an atrial specific potassium channel blocker with antiarrhythmic activity. Inakalant works by selectively blocking potassium channels in heart cells, thereby prolongs the action potential duration (APD) of cardiomyocytes and increases the effective refractory period of the atria and ventricles, which helps to terminate and prevent the occurrence of arrhythmias such as atrial fibrillation (AF). Inakalant can be used in the study of arrhythmia and cardiac electrophysiology.
    Inakalant
  • HY-117275A
    Meclofenamic acid sodium hydrate
    		Inhibitor
    Meclofenamic acid (Meclofenamate) sodium hydrate is a non-steroidal anti-inflammatory agent. Meclofenamic acid sodium hydrate is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid sodium hydrate competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
    Meclofenamic acid sodium hydrate
Cat. No. Product Name / Synonyms Application Reactivity